Affiliation:
1. School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, 144411, India
Abstract
Abstract:
Bacillus clausii is a commercial spore probiotic known to treat multiple diseases. An increased
interest in exploring the nutraceutical and probiotic properties of various microorganisms
has made researchers explore more about these bacteria. The current trends in the healthcare industry
are majorly focused on devising new therapies to avoid drug and pathogen resistance in patients.
Antimicrobial peptides have been considered a source of antibiotics for a long time. Still, getting
new therapies into the market is a big challenge. Members of the genus Bacillus have been reported
to have a broad spectrum of antimicrobial peptides. One of the least explored species under this genus
is Bacillus clausii, concerning peptide drug therapy. The applications of Bacillus clausii in
treating or preventing gut dysbiosis and respiratory infections have been largely supported in the
past two decades. Yet research is lacking in explaining the pathways at molecular levels in targeting
pathogens. In this mini-review, we are going to summarise the research that has been reported so far
about peptide extraction from Bacillus clausii, their mode of action and advantages to mankind, and
the challenges lying in the isolation of peptides.
Publisher
Bentham Science Publishers Ltd.